Evidence map›Paper›PMID 40395097›Full record

ArticleAndrology2026

Detection of germ cell neoplasia in situ and testicular cancer risk in men with testicular microlithiasis: Real world results through 10 years.

Karoline Skov Lundager, Rasmus Hassing Frandsen, Emil Durukan, Nadia Zeeberg Belhouche, Christian Fuglesang S Jensen, Peter Busch Østergren, Jens Sønksen, Mikkel Fode

Abstract read
In one paragraph

Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karoline Skov LundagerDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Rasmus Hassing FrandsenDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Emil DurukanDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Nadia Zeeberg BelhoucheDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Christian Fuglesang S JensenDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Peter Busch ØstergrenDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Jens SønksenDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Mikkel FodeDepartment of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.ORCID 0000-0002-8963-4581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGuidelines recommend biopsies for men <50 years with testicular microlithiasis and cancer risk factors to rule out germ cell neoplasia in situ. Limited data support this practice.

objectivesTo clarify the significance of testicular microlithiasis by examining pathological findings in men with testicular microlithiasis. MATERIALS AND

methodsWe reviewed charts of men diagnosed with testicular microlithiasis at a tertiary referral center from 2013 to 2023. Patient characteristics, clinical findings, and cancer risk factors including testicular hypotrophy (volume ≤12 mL), infertility, and cryptorchidism were recorded. Men with unknown fertility were offered semen analyses. Histological findings from testicular biopsies and subsequent cancers were noted. Primary endpoints were rates of germ cell neoplasia in situ and testicular cancer diagnoses.

resultsWe included 334 men (median age 33 years, range 16-73 years): 27 had testicular hypotrophy, 18 infertility, 25 cryptorchidism, and 56 multiple risk factors. The remaining 208 men had no apparent risk factors. Of these 36 were had reduced semen quality. Overall, 137 of 334 men (41%) underwent biopsies, with germ cell neoplasia in situ in 10 cases (7.3%, 95% confidence interval 3.6%-13%). Four had multiple risk factors (hypotrophy and infertility in two; hypotrophy, infertility, and cryptorchidism in two), three had hypotrophy alone, one had infertility, and two had reduced semen quality. Germ cell neoplasia in situ was unilateral in all cases and only found in testicles with testicular microlithiasis. Unilateral orchiectomy was performed in all germ cell neoplasia in situ cases, with hypotrophy found in all but one. Over a median follow-up of 4.7 years (range 1.16-11.49 years), testicular cancer developed in three men (0.9%, 95% confidence interval 0.19%-2.6%). DISCUSSION: Germ cell neoplasia in situ was only detected in cases with both testicular microlithiasis and testicular hypotrophy, and the rate of subsequent cancer development was low. This suggests that testicular microlithiasis alone does not increase cancer risk in otherwise morphologically normal testicles.

conclusionBiopsies should only be considered in men with incidental testicular microlithiasis if the testicular size is reduced.

Indexed as

CalculiNeoplasms, Germ Cell and EmbryonalTesticular DiseasesTesticular NeoplasmsAdolescentAdultAgedBiopsyHumansInfertility, MaleMaleMiddle AgedRetrospective StudiesRisk FactorsTestisYoung Adultgerm cell neoplasmsmicrolithiasissementesticular biopsytesticular carcinoma in situtesticular microcalcificationtesticular neoplasms

Identifiers

PMID40395097
PMCPMC12842850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.